Ghotbi R, Sotiriou A, Mansur R
Ludwig-Maximillian-University, Monaco, Germany.
J Cardiovasc Surg (Torino). 2010 Aug;51(4):475-80.
The purpose of this study was to report the outcome of EVAR using EXCLUDER endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz.) with low-porosity polytetrafluoroethylene (PTFE) in the medium term. We reviewed a 10-year-experience with this device to document the outcome of 100 consecutive elective EVARs with Excluder-Device performed at a single centre.
From 01.2006 to 01.2009 all elective abdominal aortic aneurysm (AAA) cases (N=100) with an abdominal aortic aneurysm (AAA; mean diameter 5.61 cm; range 4.2-7.3 cm) that were treated electively with the EXCLUDER Bifurcated Endoprosthesis were entered in an index. Anatomical and clinical evaluations and radiological results have been analyzed. Mean aortic neck length was 12.24 mm, mean proximal aortic diameter was 24.39 mm. Primary outcome that has been examined, include operative mortality, aneurysm rupture, aneurysm-related mortality, open surgical conversion, and late survival rates. The incidence of endoleak, migration, aneurysm enlargement, and graft patency have also been determined. Finally, the need for reinterventions and success of such secondary procedures were evaluated. Endoleaks were diagnosed from contrast-enhanced computed tomography, the rate of type II endoleaks was analyzed after 1, 3 and 12 months.
Mean patient age was 74.1 years (range 44-91 years); 91% were male. Mean follow-up was 20 months; 78 % of the patients had 2 or more major comorbidities, and 32 % were categorized as inappropriate for open repair. On an intent-to-treat basis, device deployment was successful in 100%. Thirty-day mortality was 0%; freedom from AAA rupture was 100%. Type II endoleak appeared directly after the procedure in 24%, after 3 months in 15% and after 12 months in 7%. The initial technical success defined as endovascular aneurysm exclusion and absence of type I endoleak was 99%. Proximal type I early endoleak occurred (detected by intraoperative DSA) in 3 patients, in 2 cases intraoperative proximal aortic cuffs were needed to seal proximal type I endoleaks. In one case we performed a proximal bending via a retroperitoneal access and sealed the endoprosthesis. Postoperatively, the size of the AAA decreased or remained unchanged in 93% after 12 months. Freedom from reinterventions was 94% after 2 years.
EVAR using the EXCLUDER-Device is a safe, effective, and durable method to prevent AAA rupture and aneurysm-related death. Assuming suitable AAA anatomy, these data justify a broad application within a wide spectrum of patients.
本研究旨在报告中期使用具有低孔隙率聚四氟乙烯(PTFE)的EXCLUDER血管内修复装置(美国亚利桑那州弗拉格斯塔夫市的W.L.戈尔联合公司)进行腹主动脉瘤腔内修复术(EVAR)的结果。我们回顾了在单一中心连续100例使用EXCLUDER装置进行的择期EVAR手术的10年经验,以记录其结果。
从2006年1月至2009年1月,所有使用EXCLUDER分叉型血管内修复装置进行择期治疗的腹主动脉瘤(AAA)病例(N = 100)均被纳入索引。对解剖学和临床评估以及影像学结果进行了分析。主动脉颈部平均长度为12.24毫米,主动脉近端平均直径为24.39毫米。已检查的主要结果包括手术死亡率、动脉瘤破裂、动脉瘤相关死亡率、开放手术转换率和晚期生存率。还确定了内漏、移位、动脉瘤增大和移植物通畅率的发生率。最后,评估了再次干预的必要性以及此类二次手术的成功率。通过增强CT诊断内漏,在术后1、3和12个月分析II型内漏的发生率。
患者平均年龄为74.1岁(范围44 - 91岁);91%为男性。平均随访时间为20个月;78%的患者有2种或更多种主要合并症,32%被归类为不适合开放修复。基于意向性分析,装置植入成功率为100%。30天死亡率为0%;无AAA破裂率为100%。II型内漏在术后即刻出现的比例为24%,3个月后为15%,12个月后为7%。初始技术成功率(定义为血管内动脉瘤隔绝且无I型内漏)为99%。3例患者发生近端I型早期内漏(术中DSA检测到),其中2例术中需要使用近端主动脉套囊来封闭近端I型内漏。1例患者通过腹膜后途径进行近端弯曲并封闭了血管内修复装置。术后12个月,93%的AAA大小减小或保持不变。2年后无需再次干预的比例为94%。
使用EXCLUDER装置进行EVAR是预防AAA破裂和动脉瘤相关死亡的一种安全、有效且持久的方法。假设AAA解剖结构合适,这些数据证明该方法可广泛应用于各类患者。